Drugs /

capox regimen

Back to Drugs List

Overview

Trade Name(s):
Xeloda-Oxaliplatin Regimen
NCI Definition [1]:
A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar regimen, XELOX, with regards to the dosing schedule for oxaliplatin.

Clinical Trials

View Clinical Trials for capox regimen

Capox regimen has been investigated in 9 clinical trials, of which 9 are open and 0 are closed. Of the trials investigating capox regimen, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for capox regimen clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and cholangiocarcinoma are the most common diseases being investigated in capox regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Capox Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating capox regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
xelox, capecitabine-oxaliplatin regimen, capecitabine-oxaliplatin, Xeloda-Oxaliplatin Regimen, capeox regimen
NCIT ID [1]:
C63596

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.